指南与共识胸部肿瘤

IV期非小细胞肺癌伴驱动基因改变的治疗:ASCO动态指南2025.1版

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1.
指南 / 共识 · J Clin Oncol · 2025-07-17

该动态指南由ASCO常设专家小组持续系统审查文献并定期更新,针对IV期非小细胞肺癌伴驱动基因改变患者的治疗推荐。本次2025.1版更新具体推荐内容未在摘要中列出,全文可于ASCO官网获取。

要点

  • ASCO动态指南针对IV期非小细胞肺癌伴驱动基因改变的治疗。
  • 由常设专家小组持续系统审查文献并定期更新。
  • 2025.1版具体推荐条款未在摘要中报告。

核心结论

  • ASCO动态指南针对IV期非小细胞肺癌伴驱动基因改变的治疗推荐定期更新,2025.1版具体推荐内容未在摘要中报告。

研究设计与样本

  • 由ASCO常设专家小组按照ASCO指南方法学手册持续系统审查健康文献并定期更新。

临床怎么用

  • 动态指南及更新不替代治疗临床医生的独立专业判断,也不考虑患者个体差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Reuss JE, Kuruvilla S, Ismaila N, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1. J Clin Oncol. 2025. PMID: 40674661. doi:10.1200/JCO-25-01061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。